dupilumab   Click here for help

GtoPdb Ligand ID: 7574

Synonyms: Dupixent® | REGN668 | SAR231893
Approved drug Immunopharmacology Ligand
dupilumab is an approved drug (EMA & FDA (2017))
Compound class: Antibody
Comment: Dupilumab is fully human monoclonal antibody against the α subunit of the IL4 receptor.
Peptide sequences for this antibody are available from its IMGT/mAb-db record. Dupilumab was produced using Regeneron's genetically engineered VelocImmune® mice which have humanized immunoglobulin gene loci and produce human:mouse hybrid antibodies that can rapidly be converted to fully human antibodies [3].
Click here for help
1. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, Hellings P, Jiao L, Wang L, Evans RR et al.. (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.
JAMA, 315 (5): 469-79. [PMID:26836729]
2. Martin JH, Huang TT, Fairhurst JL, Papadopoulos NJ. (2009)
Cytokine specific immunoglobulin for use in diagnosis, prevention and treatment ,of cell proliferative, inflammatory, allergic, respiratory, autoimmune and arthritic disorders.
Patent number: US7608693. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 02/10/2006. Publication date: 27/10/2009.
3. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, Huang TT, Poueymirou WT, Esau L, Meola M et al.. (2014)
Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice.
Proc Natl Acad Sci USA, 111 (14): 5153-8. [PMID:24706856]
4. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B et al.. (2013)
Dupilumab in persistent asthma with elevated eosinophil levels.
N Engl J Med, 368 (26): 2455-66. [PMID:23688323]